Tvardi Therapeutics Inc (fra:69C) Share Price

Company Profile

Business description
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Contact
3 Sugar Creek Center boulevard
Suite 525
Sugar LandTX77478
USA
T: +1 713 489-8654
https://www.tvarditherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12

Recommended

Margin recovery remains the key driver for this ASX healthcare share.

Brian Han | 24 July 2026

We maintain our fair value estimate for wide-moat Alphabet.

Malik Ahmed Khan, CFA | 24 July 2026

We’re encouraged that AMD will count Anthropic as a third leading AI customer, in addition to OpenAI and Meta.

Brian Colello, CPA | 23 July 2026

Index	Last price	Change	% Change
All Ordinaries	8,941.50	32.70	-0.36%
CAC 40	8,336.64	37.55	0.45%
DAX 40	24,986.25	223.13	0.90%
Dow JONES (US)	51,861.45	149.80	0.29%
FTSE 100	10,712.55	73.38	0.69%
HKSE	24,963.23	247.58	-0.98%
NASDAQ	25,046.97	90.72	-0.36%
Nikkei 225	64,611.15	1,811.45	-2.73%
NZX 50 Index	13,772.29	23.02	-0.17%
S&P 500	7,426.52	18.22	0.25%
S&P/ASX 200	8,772.30	23.40	-0.27%
SSE Composite Index	3,814.20	62.58	-1.61%